For the year ending 2025-12-31, DSGN had -$5,707K decrease in cash & cash equivalents over the period. -$54,551K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -69,792 |
| Depreciation | 622 |
| Stock-based compensation | 14,549 |
| Amortization of premiums on investment securities, net | 3,253 |
| Non-cash lease expense | -21 |
| Deferred financing costs | 427 |
| Prepaid expense and other assets | 1,376 |
| Accounts payable and other liabilities | 4,486 |
| Net cash used in operating activities | -54,358 |
| Purchases of investment securities | 291,779 |
| Proceeds from maturities of investment securities | 314,885 |
| Purchases of property and equipment | 193 |
| Net cash provided by investing activities | 22,913 |
| Proceeds from the issuance of common stock in at-the-market offering, net of issuance costs | 24,847 |
| Proceeds from the exercise of stock options | 242 |
| Issuance of common stock through employee stock purchase plan | 649 |
| Net cash provided by financing activities | 25,738 |
| Net decrease in cash and cash equivalents | -5,707 |
| Cash and cash equivalents at beginning of period | 22,563 |
| Cash and cash equivalents at end of period | 16,856 |
Design Therapeutics, Inc. (DSGN)
Design Therapeutics, Inc. (DSGN)